Dr Reisa Sperling discusses the rationale for targeting preclinical Alzheimer's disease, the latest long-term data from the Brainshuttle AD programme evaluating trontinemab, and how the PrevenTRON study could help shift Alzheimer's disease treatment towards prevention. We spoke with Dr Reisa ...

Dr Klaus Dugi discusses the first-in-human data for VNA-318, the rationale for targeting cellular energy metabolism in Alzheimer's disease, and how improving mitochondrial function could offer both symptomatic and disease-modifying benefits. We spoke with Klaus Dugi, Chief Executive Officer of ...

Prof. John-Paul Taylor discusses the phase 2b RewinD-LB findings, lessons learned from the neflamapimod programme, and the next steps towards precision medicine in dementia with Lewy bodies We spoke with Prof. John-Paul Taylor, Newcastle University, Newcastle upon Tyne, UK, at ...

Prof. George Grossberg discusses the unmet need in agitation associated with Alzheimer's disease, the rationale behind the phase 3 ADAGIO studies, and the evolving role of biomarkers and caregivers in improving patient care. We spoke with Prof. George Grossberg, Saint Louis ...

Large real-world study highlights important ethnoracial differences in amyloid positivity and their implications for diagnosis, treatment and clinical trial access As amyloid biomarkers become central to Alzheimer's disease diagnosis and treatment, a new analysis from the New IDEAS (Imaging Dementia—...

Meet the future leaders transforming neurology The touchNEUROLOGY Future Leaders 2026 programme recognizes outstanding early- and mid-career clinicians, researchers and scientists who are shaping the future of neurology. Nominated by peers across the global neurology community, these innovators are leading advances ...

We are delighted to announce Dr Ahmed Abdelhak as a touchNEUROLOGY Future Leader 2026, selected by peers as one of the neurologists changing the future of research in blood biomarkers in multiple sclerosis. We spoke with Dr Ahmed Abdelhak (Department of ...

We are delighted to announce Dr Roopa Rajan as a touchNEUROLOGY Future Leader 2026, selected by peers as one of the neurologists changing the future of Parkinson's disease and movement disorders. We spoke with Dr Roopa Rajan (All India Institute of ...

We are delighted to announce Dr ​​Robin Zhou as a touchNEUROLOGY Future Leader 2026, selected by peers as one of the neurologists changing the future of Alzheimer's disease. Dr Robin Zhou (Karolinska Institutet, Stockholm, Sweden) is an MD and PhD student ...